Efficacy of Eltrombopag with Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone on Severe Aplastic Anaemia: A Systematic Review and Meta-analysis Senlin ZhangQingwei WangShaoyan Hu Systematic Review Open access 11 May 2023 Pages: 315 - 324
Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review Małgorzata PapierzewskaAnna Waśkiel-BurnatLidia Rudnicka Systematic Review Open access 03 May 2023 Pages: 325 - 334
Evaluation of the Drug–Drug Interaction Potential of Ensitrelvir Fumaric Acid with Cytochrome P450 3A Substrates in Healthy Japanese Adults Ryosuke ShimizuTakuhiro SonoyamaRyuji Kubota Original Research Article Open access 12 May 2023 Pages: 335 - 346
A Risk-Scoring Model for Severe Checkpoint Inhibitor-Related Pneumonitis: A Case–Control Study Haiyi DengJiating DengChengzhi Zhou Original Research Article 25 April 2023 Pages: 347 - 357
Oral Capecitabine Exposures and Use of Uridine Triacetate: A 20-Year Retrospective Analysis Justin A. SeltzerNathan A. FriedmanAlicia Minns Short Communication Open access 19 April 2023 Pages: 359 - 363
Intra-Class Switch Among IL-23 Inhibitors for Plaque Psoriasis: Is It Worth It? Luigi GargiuloLuciano IbbaAlessandra Narcisi Research Letter 08 May 2023 Pages: 365 - 367
Olipudase Alfa in Non-CNS Manifestations of Acid Sphingomyelinase Deficiency: A Profile of Its Use Yahiya Y. Syed Adis Drug Q&A Open access 03 May 2023 Pages: 369 - 377
Correction to: A Cross-Sectional Study of Tampering in Xtampza ER, an Abuse-Deterrent Formulation of an Extended-Release Opioid, in a Treatment Center Population Jennifer JewellJoshua BlackRichard Dart Correction Open access 11 April 2023 Pages: 379 - 379
Correction to: A Cost‑effectiveness Analysis of iGlarLixi Versus IDegAsp and Appropriate Price Exploration of iGlarLixi for Type 2 Diabetes Mellitus Patients in China Yanqing JiangRuizhe LiuJianxin Pang Correction 28 April 2023 Pages: 381 - 381
